GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

Arexvy (respiratory syncytial virus vaccine, adjuvanted) is a brand-name intramuscular injection that’s prescribed to help prevent a lung infection that’s caused by RSV infection in adults.

Arexvy is a vaccine used to prevent certain lower respiratory infections caused by respiratory syncytial virus (RSV). Arexvy’s cost may depend on factors such as whether you have health ...

Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

GSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted the company's regulatory ...

U.K.-based biopharmaceutical company GSK plc (GSK) said on Friday that the European Medicines Agency (EMA) has accepted its ...

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...

Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...

Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's ...

The study was a phase 3 clinical trial on GSK’s Arexvy vaccine, which was published April 14 in The Lancet Respiratory Medicine. The findings were the first that tracked vaccine efficacy over ...

Over 13 million adults aged 50-59 at increased risk in the US can potentially benefit from RSV immunization 1 RSV causes an estimated 42,000 hospitalizations* each year in adults aged 50-64 years ...